Clinical Utility of lncRNAs in Urothelial Carcinoma of the Bladder: Diagnostics, Risk Stratification, and Treatment Guidance

Urothelial carcinoma of the bladder remains challenging to assess in real time. Standard tools such as white-light cystoscopy and urine cytology are essential, but both have recognized limitations, particularly for carcinoma in situ, low-grade disease and repeated long-term surveillance in non-muscle-invasive bladder cancer (NMIBC). Conventional risk models also show imperfect performance in contemporary practice, contributing to both overtreatment and delayed escalation in biologically aggressive disease. Long non-coding RNAs (lncRNAs) are emerging as attractive biomarkers because of their context-specific expression, measurable expression in tumor tissue and detectability in urine and blood, including within extracellular vesicles (EVs), such as exosomes that protect RNA from degradation. The potential clinical role of lncRNAs is determined by the specimen, molecular compartment, disease setting, and intended use. Urinary cell-free and urinary EV-associated lncRNAs currently have the strongest translational evidence for hematuria triage diagnostic support, recurrence-risk assessment, and longitudinal molecular monitoring. Tissue lncRNAs are most relevant to biological classification and prognostic refinement after transurethral resection or cystectomy, whereas blood-based lncRNAs may provide complementary information on systemic disease burden and treatment-associated response, particularly in muscle-invasive or advanced disease. Although several urinary multi-lncRNA panels have functioned as stand-alone statistical classifiers in development cohorts, no lncRNA assay has been prospectively validated to replace cystoscopy, cytology, histopathology, or established treatment-selection biomarkers in routine care. Repeatedly studied candidates include UCA1 and several exosomal/uEV-associated lncRNAs (e.g., TERC, SNHG16), while multi-lncRNA panels and combined strategies (including integration with established urine tests such as NMP22) may stabilize performance across biological and pre-analytical variability. Evidence also supports the concept of longitudinal “molecular response” monitoring using liquid-based lncRNA readouts, although truly predictive, treatment-interaction evidence remains limited. Across studies, performance is strongly influenced by the urine compartment analyzed (pellet/sediment, cell-free urine, or urinary EVs (uEVs)/exosomes) and by pre-analytical handling and normalization choices. lncRNA assays are unlikely to replace cystoscopy in the near term, but they have clear potential as decision-support tests that complement clinical risk assessment, cytology, and other urine-based platforms. This work synthesizes mechanistic and clinically annotated evidence on lncRNAs in bladder cancer, with an emphasis on urine-based and uEV/exosomal assays. The search strategy covered publications from 1 January 2015 to 30 December 2025, with emphasis on most recent clinically relevant studies, and included mechanistic studies with functional validation, liquid biopsy/urine studies, and evidence syntheses.